Skip to main content

Table 1 Baseline characteristics of the trial participants

From: A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood

Variable Total (n = 10)
Age at inclusion, y, median (IQR) 18.7 (17.9–20.2)
Male sex, n (%) 4 (40)
Age at diagnosis, m, median (IQR) 6.9 (0.1–11.4)
Mutation of ATP1A3
p.D801N 5 (50)
 Other mutations 5 (50)
Total paroxysmal events per week
 Median (IQR) 3.88 (3.19–4.85)
 Mean (SD) 4.39 (1.95)
Chronic medications, n (%) 9 (90)
 Number, median (IQR) 3 (3–4)
 Flunarizine, n (%) 8 (80)
 Acetazolamide, n (%) 2 (20)
Permanent neurologic deficiency
 Pyramidal syndrome 8 (80)
 Cerebellar syndrome 8 (80)
 Dystonia 8 (80)
 Cognitive/ behavioral dysfunction 6 (60)
  1. n (%) represents the number of patients (and the percentage of all patients) assessed in each group. Abbreviations: Y years, m months, IQR interquartile range [p25–p75]